- Home
- LXEH vs IMNN Comparison
LXEH vs IMNN Comparison
Compare LXEH & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXEH
- IMNN
- Stock Information
- Founded
- LXEH 2001
- IMNN 1982
- Country
- LXEH China
- IMNN United States
- Employees
- LXEH N/A
- IMNN N/A
- Industry
- LXEH Other Consumer Services
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- LXEH Real Estate
- IMNN Health Care
- Exchange
- LXEH Nasdaq
- IMNN Nasdaq
- Market Cap
- LXEH 12.5M
- IMNN 12.9M
- IPO Year
- LXEH 2020
- IMNN 1985
- Fundamental
- Price
- LXEH $0.36
- IMNN $4.11
- Analyst Decision
- LXEH
- IMNN Buy
- Analyst Count
- LXEH 0
- IMNN 2
- Target Price
- LXEH N/A
- IMNN $182.61
- AVG Volume (30 Days)
- LXEH 1.6M
- IMNN 63.3K
- Earning Date
- LXEH 12-30-2025
- IMNN 11-13-2025
- Dividend Yield
- LXEH N/A
- IMNN N/A
- EPS Growth
- LXEH N/A
- IMNN N/A
- EPS
- LXEH N/A
- IMNN N/A
- Revenue
- LXEH $4,585,942.00
- IMNN N/A
- Revenue This Year
- LXEH N/A
- IMNN N/A
- Revenue Next Year
- LXEH N/A
- IMNN N/A
- P/E Ratio
- LXEH N/A
- IMNN N/A
- Revenue Growth
- LXEH N/A
- IMNN N/A
- 52 Week Low
- LXEH $0.31
- IMNN $3.64
- 52 Week High
- LXEH $50.08
- IMNN $41.22
- Technical
- Relative Strength Index (RSI)
- LXEH 29.55
- IMNN 41.72
- Support Level
- LXEH $0.35
- IMNN $3.64
- Resistance Level
- LXEH $0.40
- IMNN $4.38
- Average True Range (ATR)
- LXEH 0.05
- IMNN 0.30
- MACD
- LXEH 0.06
- IMNN 0.03
- Stochastic Oscillator
- LXEH 7.82
- IMNN 40.87
About LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).